Breakthrough in cancer research

2012-06-03 13:29

Multimedia   ·   User Galleries   ·   News in Pictures Send us your pictures  ·  Send us your stories

Chicago - An experimental drug treatment may help keep a certain kind of aggressive breast cancer at bay, offering new hope for individual therapies against difficult tumours, said research released on Sunday.

The phase III trial comparing trastuzumab emtansine (T-DM1) to standard therapy for human epidermal growth factor receptor 2 (HER2 positive) breast cancer was presented at the American Society of Clinical Oncology conference in Chicago.

The international study randomised nearly 1 000 patients to receive either T-DM1 or standard therapy every three weeks. The subjects all had metastatic cancer that had spread to other parts of the body.

The trial found that progression-free survival in the T-DM1 group was 9.6 months, compared to 6.4 months in the standard therapy group, which study authors described as "clinically meaningful improvement."

"The drug worked. It was significantly better than a very effective approved therapy for HER2 overexpressing metastatic breast cancer," said lead study author Kimberly Blackwell, professor of medicine at Duke University.

"Also, as a clinician who takes care of a lot of breast cancer patients, I'm pleased that this drug has very little dose-limiting toxicity. Patients don't lose their hair from this drug.

"For patients facing metastatic breast cancer, this is a breakthrough."

The data on overall survival time showed 65% of T-DM1 patients were alive after two years, compared to 47.5% of the standard therapy patients, a threshold that fell short of the trial's predetermined limits for judging statistical significance.

More analysis of survival times is planned for later in the ongoing study.

Read more on:    cancer  |  health

Join the conversation!

24.com encourages commentary submitted via MyNews24. Contributions of 200 words or more will be considered for publication.

We reserve editorial discretion to decide what will be published.
Read our comments policy for guidelines on contributions.
NEXT ON NEWS24X

linking and moving

2015-04-22 07:36

24.com publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
3 comments
Comments have been closed for this article.

Inside News24

 
/News

Book flights

Compare, Book, Fly

Traffic Alerts
There are new stories on the homepage. Click here to see them.
 
English
Afrikaans
isiZulu

Hello 

Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.


Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire 24.com network.

Settings

Location Settings

News24 allows you to edit the display of certain components based on a location. If you wish to personalise the page based on your preferences, please select a location for each component and click "Submit" in order for the changes to take affect.




Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.